Earl Avramis

1.5k total citations
15 papers, 986 citations indexed

About

Earl Avramis is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Earl Avramis has authored 15 papers receiving a total of 986 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Earl Avramis's work include CAR-T cell therapy research (6 papers), Melanoma and MAPK Pathways (5 papers) and Immunotherapy and Immune Responses (3 papers). Earl Avramis is often cited by papers focused on CAR-T cell therapy research (6 papers), Melanoma and MAPK Pathways (5 papers) and Immunotherapy and Immune Responses (3 papers). Earl Avramis collaborates with scholars based in United States, Vietnam and France. Earl Avramis's co-authors include Antoni Ribas, Thinle Chodon, Begonya Comin-Anduix, Mohammad Atefi, Thomas G. Graeber, Deborah J. Wong, Amanda Lassen, Michael Cerniglia, David Foulad and Lídia Robert and has published in prestigious journals such as Blood, PLoS ONE and Scientific Reports.

In The Last Decade

Earl Avramis

14 papers receiving 975 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Earl Avramis United States	12	711	457	347	100	62	15	986
Peter A. Prieto United States	13	828 1.2×	659 1.4×	233 0.7×	82 0.8×	51 0.8×	43	1.1k
Eileen E. Parkes United Kingdom	12	541 0.8×	435 1.0×	441 1.3×	157 1.6×	149 2.4×	36	1.0k
Lukas Baitsch Switzerland	13	935 1.3×	1.0k 2.2×	385 1.1×	68 0.7×	108 1.7×	13	1.5k
Erin McNamara United States	8	624 0.9×	366 0.8×	336 1.0×	89 0.9×	84 1.4×	18	971
Eva Ellebæk Denmark	21	1.2k 1.7×	1.0k 2.2×	392 1.1×	94 0.9×	56 0.9×	71	1.6k
Inge Verbrugge Netherlands	17	621 0.9×	443 1.0×	555 1.6×	113 1.1×	122 2.0×	23	1.1k
Divis Khaira United States	8	393 0.6×	239 0.5×	378 1.1×	101 1.0×	81 1.3×	8	784
Wanhong Zhao China	17	432 0.6×	322 0.7×	396 1.1×	51 0.5×	196 3.2×	54	978
Bruno A. Duso Italy	9	422 0.6×	189 0.4×	354 1.0×	186 1.9×	255 4.1×	21	879
Megan Duggan United States	14	326 0.5×	361 0.8×	222 0.6×	52 0.5×	55 0.9×	25	631

Countries citing papers authored by Earl Avramis

Since Specialization

Citations

This map shows the geographic impact of Earl Avramis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Earl Avramis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Earl Avramis more than expected).

Fields of papers citing papers by Earl Avramis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Earl Avramis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Earl Avramis. The network helps show where Earl Avramis may publish in the future.

Co-authorship network of co-authors of Earl Avramis

This figure shows the co-authorship network connecting the top 25 collaborators of Earl Avramis. A scholar is included among the top collaborators of Earl Avramis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Earl Avramis. Earl Avramis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Lu, Dan, Soohyung Park, Mark B. Landon, et al.. (2025). A novel CD3ε fusion receptor allows T cell engager use in TCR-less allogeneic CAR T cells to improve activity and prevent antigen escape. Molecular Therapy. 33(9). 4570–4583.

Yang, Bi-Huei, Wen-I Yeh, Mochtar Pribadi, et al.. (2021). Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape. Blood. 138(Supplement 1). 2793–2793. 4 indexed citations

Nowicki, Theodore S., Helena Escuin-Ordinas, Earl Avramis, et al.. (2018). Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. Journal of Immunotherapy. 41(5). 248–259. 2 indexed citations

Ribas, Antoni, Daniel Sanghoon Shin, Jesse M. Zaretsky, et al.. (2016). PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunology Research. 4(3). 194–203. 302 indexed citations

Atefi, Mohammad, Bjoern Titz, Jennifer Tsoi, et al.. (2016). CRAF R391W is a melanoma driver oncogene. Scientific Reports. 6(1). 14 indexed citations

Atefi, Mohammad, Bjoern Titz, Earl Avramis, et al.. (2015). Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Molecular Cancer. 14(1). 27–27. 51 indexed citations

Atefi, Mohammad, Earl Avramis, Amanda Lassen, et al.. (2014). Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma. Clinical Cancer Research. 20(13). 3446–3457. 285 indexed citations

Wong, Deborah J., Earl Avramis, Douglas Matsunaga, et al.. (2014). Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function. Cancer Immunology Research. 2(5). 459–468. 17 indexed citations

Wong, Deborah J., Lídia Robert, Mohammad Atefi, et al.. (2014). Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Molecular Cancer. 13(1). 194–194. 85 indexed citations

10.

Ma, Chao, Ann Cheung, Thinle Chodon, et al.. (2013). Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy. Cancer Discovery. 3(4). 418–429. 112 indexed citations

11.

Ibarrondo, F. Javier, Otto O. Yang, Thinle Chodon, et al.. (2013). Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab. PLoS ONE. 8(10). e76829–e76829. 14 indexed citations

12.

Escuin-Ordinas, Helena, Mohammad Atefi, Yong Fu, et al.. (2013). COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Molecular Oncology. 8(2). 250–260. 31 indexed citations

13.

Escuin-Ordinas, Helena, Mark Elliott, Mohammad Atefi, et al.. (2013). PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. Journal for ImmunoTherapy of Cancer. 1(1). 14–14. 14 indexed citations

14.

Avramis, Vassilios I., Earl Avramis, William Hunter, & Melissa C. Long. (2009). Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL).. PubMed. 29(1). 299–302. 33 indexed citations

15.

Avramis, Vassilios I., Sagrario Martín‐Aragón, Earl Avramis, & Barbara L. Asselin. (2007). Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.. PubMed. 27(4C). 2561–72. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact